TABLE 4.
Successful responses by treatment groupa
| Endpoint | No. of subjects with response/ No. of subjects in the population (%) for anidulafungin dose group (mg)
|
||
|---|---|---|---|
| 50 | 75 | 100 | |
| Global response | |||
| EOT | 21/25 (84) | 27/30 (90) | 25/28 (89) |
| FU | 13/18 (72) | 22/26 (85) | 20/24 (83) |
| Clinical response | |||
| EOT | 22/25 (88) | 27/30 (90) | 25/28 (89) |
| FU | 13/18 (72) | 22/26 (85) | 20/24 (83) |
| Microbiological responseb | |||
| EOT | 21/25 (84) | 28/30 (93) | 25/28 (89) |
| FU | 14/18 (78) | 22/26 (85) | 21/24 (88) |
a
Results are presented for evaluable patients.
b
Analyzed on a per-patient basis